FDA says Anne’s Daye marketed CBD-coated tampons and vaginal screening kits without required device clearance or approval.
What happened
During a July 8–11, 2024 inspection in Bulgaria and a review of its website, FDA found Anne’s Daye making and promoting CBD Daye Tampons and Vaginal Microbiome Screening Kits. FDA said the tampon was cleared only to absorb menstrual discharge but was promoted for period pain, and the screening kit was promoted to diagnose yeast infections, BV, STIs, fertility issues, and other conditions. FDA also said complaints about CBD tampons on Trustpilot were answered but not logged and evaluated in the complaint system.
What FDA found
The CBD Daye Tampon is adulterated because the company lacks an approved premarket approval application or investigational device exemption for it.
section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)The CBD Daye Tampon is misbranded because the company promoted it for period pain, a major change to the cleared intended use, without a new 510(k) notification.
section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)(ii) and (i)The Vaginal Microbiome Screening Kit is adulterated because the company lacks an approved premarket approval application or investigational device exemption for it.
section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)The Vaginal Microbiome Screening Kit is misbranded because the company did not notify FDA before introducing it into commercial distribution as required by 510(k).
section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)The company failed to establish and maintain procedures for receiving, reviewing, and evaluating complaints, and did not log and evaluate Trustpilot complaints about CBD tampons.
21 CFR 820.198(a)
What FDA wants
FDA asks the company to respond in writing within 15 business days with the steps taken or planned, documentation of corrective actions, and a timetable for any delayed actions. FDA also says the devices are subject to detention without physical examination until the violations are addressed.
Who should pay attention
- brands selling CBD-containing menstrual or vaginal products
- contract manufacturers and importers of tampons or at-home diagnostic kits
- quality teams handling consumer complaints from public review sites
This is a summary. Read the original letter on fda.gov.